Full Press Release Details
Pharmaceuticals ANNOUNCES STOCK SPLIT
HEIGHTS, NJ, July 2, 2025 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"),
a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split
on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day.
Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol "CYCC". The new CUSIP number
for the shares of common stock following the reverse stock split is 23254L876.
the effectiveness of the reverse stock split, every 15 shares of the Company's issued and outstanding shares of common stock will
automatically convert into one issued and outstanding share of common stock. No fractional shares will be issued as a result of the reverse
stock split. Instead, any fractional shares that would have resulted from the split will be rounded up or down to the next whole number,
as applicable. The reverse stock split affects all shareholders uniformly and will not alter any shareholder's percentage interest
in the Company's outstanding shares of common stock, except for adjustments that may result from the treatment of fractional shares.
reverse stock split at a ratio of 1-for-15 shares was approved by the Company's board of directors and its stockholders. The Company
will file a Certificate of Amendment with the Secretary of State of the State of Delaware to reflect the reverse stock split occurring
on July 7, 2025. The pre-reverse stock split number of shares of common stock issued and outstanding is 23,759,475 shares and the post-reverse
stock split number of shares of common stock issued and outstanding will be 1,583,965 shares.
Cyclacel Pharmaceuticals, Inc.
is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology.
The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological
malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates
addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking
statements include, among other things, Cyclacel's future plans and prospects, Cyclacel's anticipated cash runway and the
planned timing of data results and continued development of plogosertib. Factors that may cause actual results to differ materially include
market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated
with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel's
ability to regain and maintain compliance with Nasdaq's continued listing requirements, although no assurance to that effect can
be given. You are urged to consider statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast," "designed,"
"goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list
and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other
periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise.
Pharmaceuticals, Inc.
Dr. Doris Wong Sing Ee
Pharmaceuticals, Inc.